Antidiabetic and Antidyslipidemic Activities of Dryopteris Filix-Mas Methanol Leaf Extract in Alloxan-Induced Diabetic Rats
doi.org/10.26538/tjnpr/v5i12.22
Keywords:
Diabetes, Lipid profile, Dryopteris filix-mas, Antidiabetic activity, Antidyslipidemic activityAbstract
Diabetes mellitus, a chronic metabolic disease with significant morbidity and mortality, has been associated with changes in lipid profile. Dryopteris filix-mas has been widely explored in treatment and management of various disorders. The antidiabetic and antidyslipidemic effects of Dryopteris filix-mas in alloxan-induced diabetic rats were investigated in Wistar rats. Thirty (30)adults male Wistar rats used were grouped into: 1 (Normal control); 2 (Untreated alloxan induced-diabetic rats); 3 (Diabetic rats administered 500mg/kg metformin); 4 (Diabetic rats administered 100mg/kg Dryopteris filix methanol leaf extract). 5 (Diabetic rats administered 250mg/kg Dryopteris filix methanol leaf extract); 6 (Diabetic rats administered 500 mg/kgDryopteris filix methanol leaf extract). The rats were sacrificed after 21 days. The serum was used for biochemical assay of glucose, cholesterol, triglyceride, high density lipoprotein (HDL)and low-density lipoprotein (LDL), using standard procedures. Dryopteris filix leaf extract significantly (p<0.05) reduced blood glucose levels in rats after initial increase in glucose following diabetes induction. Induction of diabetes in rats significantly (p<0.05) increased serum cholesterol, triglyceride and LDL levels, while significantly reducing HDL levels in diabetic rats. However, administration of varying doses of Dryopteris filix-mas extract significantly (p<0.05) decreased levels of cholesterol, triglyceride and LDL with corresponding increase in level of HDL. The observed changes compared well with the group administered metformin.mThe methanol leaf extract of Dryopteris filix-mas, thus, improved serum lipid profile, in diabetic rats, along with having antihyperglycemic activity.
References
Roper NA, Bilous RW, Kelly WF, Unwin NC, Connolly VM. Excess mortality in a population with diabetes and the impact of material deprivation: longitudinal, populationbased study. Br Med J. 2001; 332(7299):1389-1393.
NCD Risk Factor Collaboration. Worldwide trends in diabetes since 1980: A pooled analysis of 751 populationbased studies with 4.4 million participants. Lancet. 2016; 387(10027):1513-1530.
Schofield JD, Liu Y, Rao-Balakrishna P, Malik RA, Soran H. Diabetes Dyslipidemia. Diabetes Ther. 2016; 7(2):203-219.
Bahiru E, Hsiao R, Phillipson D, Watson KE. Mechanisms and treatment of dyslipidemia in diabetes. Curr Cardiol Rep. 2021; 23(4):26.
Sofowora A. Medicinal plants and traditional medicine in Africa. John Wiley & Sons ltd. New York. 1982.
Tagarelli G, Tagarelli A, Piro A. Folk medicine used to heal malaria in Calabria (southern Italy). J Ethnobiol Ethnomed.2010; 6(27):1-16.
Uwumarongie HO, Enike MA, Bafor EE. Pharmacognostic evaluation and gastrointestinal activity of D. filix-mas. Ewemen J Herb Chem Pharmacol Res. 2016; 2(1):19-25.
Erhirhie EO, Ilodigwe EE, Ajaghaku DL, Umeokoli BO, Eze PM. Antioxidant Activities of the Leaf Extract and Fractions of Dryopteris filix-mas (L.) Schott could be Attributed to The Abundance of Polyphenol Compounds. Biol Med Nat Prod Chem. 2020; 9(1):1-6.
Erhirhie EO, Emeghebo CN, Ilodigwe EE, Ajaghaku DL, Umeokoli BO, Eze PM, Ngwoke KG, Okoye FBC. Dryopteris filix-mas (L.) Schott ethanolic leaf extract and fractions exhibited profound anti-inflammatory activity. Avicenna J Phytomed. 2019; 9(4):396-409.
Erhirhie E, Anyim C, Okezie M, Igboeme S, Ilodigwe E. Evaluation of Wound Healing Properties of Dryopteris filix-mas Leaf and Root Extracts on Albino Rats. Iran J Pharm Sci. 2021; 17(1):79-90.
Allain CC, Poon LS, Chan CS, Richmond W, Fu PC. Enzymatic determination of total serum cholesterol. Clin Chem. 1974; 20(4):470-475.
Castelli WP, Doyle JT, Gordon T, Hames CG, Hjortland MC, Hulley SB, Kagan A, Zukel WJ. HDL Cholesterol and Other Lipids in Coronary Heart Disease: Cooperative Lipoprotein Phenotyping Study. Circul. 1977; 55(5):767-772.
Fossati P and Prencipe L. Serum triglycerides determined colorimetrically with an enzyme that produces hydrogen peroxide. Clin Chem. 1982; 28(1):2077-2080.
Friendewald WT, Levy RT, Fredrickson DS. Estimation of the concentration of low-density lipoprotein cholesterol in plasma without use of the preparative ultracentrifuge. Clin Chem. 1972; 18(6):499-502.
Lenzen S. The mechanisms of alloxan- and streptozotocininduced diabetes. Diabetologia. 2008; 51(2):216-226.
Macdonald IO, Mohammed AA, Adeboye AO. Alloxaninduced diabetes, a common model for evaluating the glycemic-control potential of therapeutic compounds and plants extracts in experimental studies. Med. 2017; 53(6):365-374.
Musi N, Hirshman MF, Nygren J. Metformin increases AMP-activated protein kinase activity in skeletal muscle of subjects with type 2 diabetes. Diabetes 2002; 51(7):2074-2081.
Ikeda T, Iwata K, Murakami H. Inhibitory effect of metformin on intestinal glucose absorption in the perfused rat intestine. Biochem Pharmacol. 2000; 59(7):887-890.
Song, R. Mechanism of Metformin: A tale of two sites. Diabetes Care. 2016; 39(2):187-189.
Buse JB, DeFronzo RA, Rosenstock J. The primary glucose-lowering effect of metformin resides in the gut, not the circulation: results from short-term pharmacokinetic and 12-week dose-ranging studies. Diabetes Care. 2016; 39(2):198–205.
Saudek CD and Young NL. Cholesterol metabolism in diabetes mellitus. Diabetes. 1981; 30(2):76-81.
Nikkila EA and Hormila P. Serum lipids and lipoproteins in insulin treated diabetes. Diabetes. 1978; 27(11):1078-1086.
Published
How to Cite
Issue
Section
License
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.
